Losartan Potassium
Product Images NDC 16590-952

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 16590-952). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Losartan 100mg Label)

This is a description of a medication that contains Losartan potassium USP 100mg. The medication is packaged and distributed by a company called STAT Gainesville in the USA. The medication comes in a box with NDC code 16590-952-30 and each tablet contains 100mg of the active ingredient. The medication is also associated with a number of other codes, including a sample code.*

FDA Label Image

Structural Formula (Losartanpotassiumusp Figure 01)

FDA Label Image

Image (Losartanpotassiumusp Figure 02)

FDA Label Image

Image (Losartanpotassiumusp Figure 03)

This text suggests that the effectiveness of two medications, Atenolol and Losartan Potassium Tablets, were compared in reducing the risk of fatal/non-fatal strokes among patients. The adjusted risk reduction of Losartan Potassium Tablets was found to be 25% with a significance level of p=0.001. The study was conducted for 60 months and the data was collected at different intervals (6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months).*

FDA Label Image

Image (Losartanpotassiumusp Figure 04)

FDA Label Image

Image (Losartanpotassiumusp Figure 05)

This is a statistical comparison between two treatments, one being Losartan Potassium Tablets, and the other is Placebo, to evaluate their effectiveness in reducing the risk of an undescribed medical condition. The graph shows the percentage of patients and the Risk Reduction with P-values. The P-value for Losartan is 0.022, indicating a statistically significant reduction in the risk when compared to Placebo. The graph also shows the duration of the study that lasted for several months.*

FDA Label Image

Logo Image (Losartanpotassiumusp Figure 07)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.